Analysts at Goldman Sachs note that news over the weekend from Shire (Nasdaq: SHPGY) that the FDA had responded to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE